Prognostic factors of surgical management for heart failure patients with reduced left ventricular ejection fraction

Mahmoud Yousef Ibrahim Abuharb1, Liu Kaiwen1, Huang Zhuhui1

  • 1Capital Medical University Affiliated Anzhen Hospital, Cardiovascular Surgery Department, 100029, China, Beijing.

Heliyon
|March 4, 2024
PubMed

Insights

Coronary artery bypass grafting (CABG) outcomes for heart failure patients with reduced ejection fraction are influenced by specific risk factors. Older age, diabetes, renal insufficiency, and prior PCI increase adverse events post-CABG.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Vascular Surgery

Background:

  • Coronary artery disease (CAD) management includes pharmaceutical and surgical options.
  • Coronary artery bypass grafting (CABG) is preferred for CAD patients with low ejection fraction (EF) due to better outcomes.
  • Heart failure with reduced ejection fraction (HFrEF) presents unique challenges in surgical candidates.

Purpose of the Study:

  • To identify factors associated with poor outcomes after CABG in HFrEF patients.
  • To compare outcomes between on-pump CABG (ONCAB) and off-pump CABG (OPCAB) in this population.
  • To determine predictors of major cardiovascular and cerebrovascular adverse events (MACCE) post-CABG.

Main Methods:

  • Retrospective review of 500 CAD patients with LVEF ≤40% undergoing ONCAB or OPCAB.
  • Analysis of clinical and surgical data, including postoperative mortality, morbidity, and MACCE.
  • Utilized univariate and multivariate COX regression to identify risk factors.

Main Results:

  • 64 out of 500 patients (12.8%) experienced MACCE.
  • Univariate analysis identified age ≥65, diabetes, and renal insufficiency as risk factors.
  • Multivariate analysis added previous percutaneous coronary intervention (PCI) as a significant risk factor.

Conclusions:

  • Age, diabetes, preoperative renal insufficiency, and prior PCI are significant predictors of MACCE post-CABG in HFrEF patients.
  • These findings aid in risk stratification and patient selection for CABG.
  • Optimizing preoperative conditions may improve outcomes for these high-risk patients.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338